AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03441334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency rTMS
Description: Participants in the intervention group will receive 1200 stimuli at the intensity of 90% of resting motor threshold via an air-filmed coil placed on the vertex. The stimulation will be delivered across 24 sessions (in 10 weeks). Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
Study NCT03441334 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Participants in the sham group will receive the same duration of stimulation via a sham coil placed on the vertex.Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
Study NCT02008279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 mg CNTO 3157
Description: A single subcutaneous (SC) (under the skin) injection of 100 mg CNTO 3157
Study NCT02008279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 300 mg CNTO 3157
Description: 2 SC injections of CNTO 3157 providing a total dose of 300 mg
Study NCT02008279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 600 mg CNTO 3157
Description: 4 SC injections of CNTO 3157 providing a total dose of 600 mg
Study NCT02008279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 300 mg CNTO 3157
Description: 300 mg of CNTO 3157 as an intravenous (IV) infusion (into a vein) administered over a period of 30 minutes
Study NCT02008279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injections of placebo (number of injections to equal number of injections of CNTO 3157)
Study NCT01907542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stapled skin closure
Description: as above
Study NCT01907542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monocryl skin suture
Description: as above
Study NCT00395863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multihance
Description: 0.5 M at a single injection
Study NCT00395863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 - Magnevist
Description: 0.5 M Magnevist at a single dose injection
Study NCT00682448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.
Study NCT00682448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo. Subjects will remain on placebo for 6 months.
Study NCT01256151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam tablet
Description: 1 mg single dose of alprazolam conventional tablet
Study NCT01256151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam sublingual
Description: 1 mg single dose of alprazolam sublingual tablet
Study NCT04442971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Stimulation
Description: Patients wear headphones for 30 minutes/day over a period of four weeks and listen to their preferred music.
Study NCT04442971 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Stimulation
Description: Patients wear headphones for 30 minutes/day over a period of four weeks and listen to an audio book.
Study NCT04442971 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No Auditory Stimulation
Description: Patients wear headphones for 30 minutes/day over a period of four weeks and hear silence.
Study NCT02549430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)
Study NCT02549430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Continuation of prior anastrozole 1mg/day orally in a continuous regimen
Study NCT02549430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Continuation of prior letrozole 2.5mg/day orally in a continuous regimen
Study NCT02549430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Continuation of prior exemestane 25mg/day orally in a continuous regimen
Study NCT02549430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen
Study NCT02171845 — intervention group
Intervention type: OTHER
Intervention: surgical biopsies
Study NCT03862144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant/Palonosetron
Study NCT01715220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual nitroglycerine
Description: A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician
Study NCT01715220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sublingual nitroglycerine
Description: A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician
Study NCT01689675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer based pain management
Study NCT01689675 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer based pain management
Study NCT00790686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insertion of Memokath 051
Description: Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.
Study NCT03332914 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent therapy
Description: The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
Study NCT02465983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-meso-19 T cells
Description: A single dose of CART-meso-19 cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting. Patients will receive CART cell treatment on an outpatient basis.
Study NCT02465983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells
Study NCT03384862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 5 μg/d vitamin B12 to be given orally. This is a standard nutritional supplement commonly used in the US.
Study NCT03384862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills, with same appearance as intervention pills.
Study NCT02475226 — intervention group
Intervention type: OTHER
Intervention: type of the brain injury
Description: epidural hematoma
Study NCT02475226 — intervention group
Intervention type: OTHER
Intervention: type of the brain injury
Description: subdural hematoma
Study NCT02475226 — intervention group
Intervention type: OTHER
Intervention: type of the brain injury
Description: subarachnoid hematoma
Study NCT02475226 — intervention group
Intervention type: OTHER
Intervention: type of the brain injury
Description: intraparenchymal hematoma
Study NCT02475226 — intervention group
Intervention type: OTHER
Intervention: type of the brain injury
Description: scull fracture
Study NCT02475226 — intervention group
Intervention type: OTHER
Intervention: type of the brain injury
Description: brain contusion
Study NCT01782573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: (i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
Study NCT01782573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: (i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
Study NCT03999723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Oral vitamin C (ascorbic acid) 1000 mg daily will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS as combination treatment.
Study NCT03999723 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules (two capsules once daily) will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS.
Study NCT01686776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 123 I-HSA + 125 I HSA
Description: Compare and validate the method of measuring albumine turnover rate
Study NCT01686776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 123 I-HSA + 125 I HSA
Description: Compare and validate the method of measuring albumine turnover rate
Study NCT02650999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg intravenously (IV)
Study NCT02389023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard gauze dressing
Description: Standard gauze dressing with tape will be placed over the surgical incision in the operating room and left on the incision as dictated by standard of care
Study NCT02389023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prevena Incision Management system
Description: The Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing.
Study NCT01161355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: Tablets of AZD9668 and IV dose of \[C14\]AZD9668
Study NCT04935892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slippers
Description: Patients in the intervention group wear slippers when out of bed
Study NCT00844155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir 75 mg
Description: The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.
Study NCT01923142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Outer-Root-Sheath Melanocytes Suspension
Description: The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
Study NCT01923142 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
Study NCT03010306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CASITA
Study NCT02114411 — intervention group
Intervention type: PROCEDURE
Intervention: GastroPanel test
Description: Dyspeptic patients will be referred for the GastroPanel test, containing four biomarkers specific for the gastric mucosa: 1) Pepsinogen I (P-PGI), 2) Pepsinogen II (P-PGII), 3) Gastrin-17 (P-G-17) and 4) H. pylori antibody (P-HpAb).
Study NCT02114411 — intervention group
Intervention type: PROCEDURE
Intervention: Gastroscopy
Description: Dyspeptic patients will undergo gastroscopy examination, with targeted biopsies from the antrum and corpus, following the protocol of the OLGA classification for chronic gastritis and Sydney Classification.
Study NCT02080247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Skin care regimen with Calmoseptine ointment
Description: Application of Calmoseptine Ointment for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters).
Study NCT02080247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Skin care regimen with Destin ointment
Description: Application of Destin for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters). Patients will receive treatment with Destin Maximum Strength 40% Zinc Oxide Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
Study NCT02470468 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC add on to SOC
Description: DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
Study NCT02470468 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVAC and immune enhancers add on to SOC
Description: DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
Study NCT02470468 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Chemotherapy
Description: SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
Study NCT01180478 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: White Light
Description: White Light Cystoscopy
Study NCT01180478 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Narrow Band Imaging
Description: Narrow Band Imaging
Study NCT01993212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 12.5 mg or 25 mg
Study NCT01993212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel 1.62%
Study NCT01993212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsules
Study NCT01993212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Study NCT01993212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gel
Study NCT01993212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Study NCT04415957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Tape
Description: The subject's trunk was passively extended for ET placement. The ET was placed on the chest wall and abdomen, considering the origins and insertions of the following muscles: rectus abdominis, internal oblique, and internal intercostal. The intervention lasted 14 days, therefore, the participants remained with the tapes for two consecutive weeks. Due to the adhesive durability of ETs (6 weeks on average), the participants were asked to return to change the ET after seven days.
Study NCT00362414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual Growth Factor
Description: 10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation~30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation
Study NCT04591730 — intervention group
Intervention type: OTHER
Intervention: First time father questionnaire self-administration
Description: The first-time father questionnaire will be self-administrated to subjects 1 month post-birth.
Study NCT01505270 — intervention group
Intervention type: OTHER
Intervention: Retrospective case study
Description: Retrospective case study
Study NCT02418780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: 6-month Tai Chi exercise program meeting 2 times per week plus DVD for home practice
Study NCT00215995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: As outlined in Detailed Description
Study NCT00215995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: As outlined in Detailed Description
Study NCT00215995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD 1839
Description: As outlined in Detailed Description
Study NCT00636675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Falls QI
Description: Falls uses the Falls Management Program (AHRQ); it is familiar to nursing homes, uses minimal researcher time, is adaptable, and simulates real word quality improvement practices. Falls is delivered over 3 months. Components include:~1. In-House Falls Coordinator training on content and falls processes.~2. Case-based modules about fall prevention and tailored for various team members.~3. Academic Detailing in which researcher consults with staff regarding challenging residents with falls.~4. Audit and Feedback. Discussions about comparison of nursing home's current practice on fall-related process and outcome measures, and how it compares with the median and the 90th percentile of peer NHs.~5. Toolbox: Handbook of useful measures and worksheets.
Study NCT00636675 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect
Description: Connect, delivered over 12 weeks, helps nursing home staff learn interactions that increase exchange of new information, number and quality of connections among staff, and improve problem-solving about patient care. Protocols:~1. In-class learning sessions introduce interaction strategies.~2. Relationship map protocols assist staff to examine existing interaction patterns and agree on goals for improvement. Individuals develop their own relationship maps and use them to practice new horizontal and vertical connections and self-monitoring their own interactions.~3. Researcher facilitates authentic learning which occurs when learners directly and independently apply concepts. In-house staff volunteers and are facilitated to assume a mentoring role.
Study NCT03561103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Client-Centered Representative Payee
Description: CCRP is a structural intervention wherein Social Security authorizes a representative payee to serve as financial manager for people who need help managing their money. By helping clients to consistently pay their bills including rents and utilities, CCRP may redirect the expenditure of participants' resources toward improved health behaviors. Shifting the focus of material and biopsychosocial resources may change the context in which health behaviors are produced, contributing to higher rates of adherence and viral suppression. CCRP modifies the implementation of a current policy of the Social Security Administration (SSA) to create an intervention that is highly replicable.
Study NCT01133899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: guanidinoacetic acid
Description: 2.4 grams of guanidinoacetic acid
Study NCT01133899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GAA-4
Description: 4.8 grams of guanidinoacetic acid
Study NCT01133899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GAA-1
Description: 1.2 grams of guanidinoacetic acid
Study NCT01133899 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: celulose